Announced Thu, 25 Jun · 18:18 IST
Jagsonpal Pharma appoints Anil Matai as Independent Director
Management Changes View source PDF
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+7.6%1-day move
₹223.00
prior close
₹222.32
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.5+2.4+2.7—+7.6+6.5+5.3+6.6+6.7+2.6+0.0———
Up moveDown movePending
AI summary
Jagsonpal Pharmaceuticals has appointed Anil Kumar Matai as Non-Executive Independent Director for 5 years from June 25, 2026, subject to shareholder approval. Matai brings 35 plus years of pharma experience, including ex-CEO of Novartis India and former President and MD of Zydus Healthcare, and currently heads OPPI.
Likely market impact
Adds a seasoned pharma industry leader to the board, strengthening governance and strategic oversight. Neutral to mildly positive for shareholders.